Skip to main content
Equibles
CAI logo

CAI · Caris Life Sciences, Inc. · Metrics

Track CAI — free

Use CAI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CAI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.35 +1.24 (+3.99%) At close · Oct 21
Russell 1000 member Rebalance outlook locked
Market Cap
$9.14B
Shares
282.60M
Volume · Oct 21 2.23M Avg daily vol (3M) 4.91M

CAI metrics

83 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$32.35
Market cap
$9.14B

Price action

20 metrics
Price change (1W)
+6.9%
Price change (30D)
+2.8%
Price change (3M)
+110.3%
Price change (6M)
+57.8%
Price change (YTD)
+19.9%
Price change (1Y)
+2.6%
Trailing year
Price change (5Y)
—
52-week high
$32.35
52-week low
$14.55
Change from 52-week high
+0.0%
Change from 52-week low
+122.3%
Annualized volatility
68.5%
Annualized volatility (3M)
77.7%
Beta
1.4
RSI (14D)
63.1
Price vs SMA 50
+17.3%
Price vs SMA 200
+51.5%
Avg volume (3M)
4.91M
Relative volume
0.5
Average dollar volume
$124.49M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
282.60M

Valuation

12 metrics
P / E (TTM)
3.9
Trailing earnings · reciprocal yield 25.7%
PEG ratio
—
EV / revenue
8.8×
reciprocal yield 11.4%
EV / EBITDA
50.0×
reciprocal yield 2.0%
EV / EBIT
56.8×
reciprocal yield 1.8%
P / sales
9.2×
reciprocal yield 10.8%
P / book
15.4
reciprocal yield 6.5%
FCF yield
1.4%
TTM · current market cap
Buyback yield
0.2%
P / FCF
73.8
reciprocal yield 1.4%
P / operating cash flow
54.2
reciprocal yield 1.8%
Earnings yield
1.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
15.5%
Trailing 12 months
Net margin
10.6%
Gross profit (TTM)
—
Operating profit (TTM)
$153.26M
Net income (TTM)
$105.14M
Trailing 12 months
Diluted EPS (TTM)
$8.32
FCF margin
12.5%
Effective tax rate
-0.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.04

Growth

11 metrics
Revenue growth YoY
+45.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$989.61M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+335.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
17.8%
Return on assets
8.6%
Debt / equity
0.7
Current ratio
5.5
EBITDA (TTM)
$174.00M
Free cash flow (TTM)
$123.96M
Quick ratio
5.5
Interest coverage
3.3
Net debt / EBITDA
-2.5
Return on invested capital
—
Trailing 12 months
Net cash
$440.64M
Latest balance sheet
Cash & equivalents
$819.90M
Total assets
$1.23B
Total debt
$393.15M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$168.56M
Capital expenditures (TTM)
$44.60M
R&D (TTM)
$117.14M
SG&A (TTM)
—
Stock compensation (TTM)
$65.11M
R&D / revenue
11.8%
Stock compensation / revenue
6.6%

Ownership (13F)

9 metrics
13F filers
248
13F filer change QoQ
+45
Institutional ownership
54.9%
Conviction holders (share of 13F filers)
2.4%
Crowding (high-turnover and private-fund holders)
18.1%
Private-fund adviser ownership
16.5%
Active holders' share change QoQ
+0.4%
Holder tenure
4.2
Price vs estimated holder cost
-16.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.8%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 2.5 days to cover
Days to cover
2.5d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$27.20M
Insider-sentiment score
8 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2019410 CUSIP 142152107 13F (30d) 37 filings 37 filers Visit website Investor relations